People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Recruiting · NCT07207148 · Registry updated 2026-03-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists | Body Weight, Body Weight Changes, CNS demyelinating autoimmune disease, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, nutritional disorder, obesity disorder, overnutrition | Recruiting | Not stated | 2026-03-17 | NCT07207148 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| Northwestern University | 381 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Northwestern Memorial Hospital | Chicago | United States | 129 |